Scientific Advisory Board (SAB)
Although basic research is important, we’re about application, i.e. healthspan engineering in humans.
Our SAB consists of members who are truly committed to – and taking action in – the development of solutions to slow and ultimately reverse age related functional decline in humans to increase healthy years.
We mourn the loss of our ally, leader, mentor and dear friend Bill Vaughan
William Vaughan PhD
PhD UC Berkeley 1974 in medical physics and biophysics. Compared the proteomics in young vs old mice in kidney and various parts of the brain (thesis advisor, Melvin Calvin, Nobel Prize winner)
Bill had spent three decades applying nutritional research to human preventive medicine and exercise performance, and funds his own human ageing research. Longtime member of the American Aging Association.
Richard G. Cutler PhD
Dr Cutler is an internationally known Molecular Biogerontologist. He has over 120 published papers, edited five books on the subject and organized numerous symposiums all aimed towards gaining a better understanding of the biological nature of human aging process and how it might be controlled to increase the healthy and productive years of life (health span).
Lord Lee-Benner, M.D., F.A.C.E.
With more than 40 years experience, Dr. Lee-Benner pioneered the field of Clinical Age Management. Dr. Lee-Benner is Fellow Emeritus, American College of Clinical Endocrinology and the Endocrine Society. He is board certified in neurology and psychiatry, and expert in multiple disciplines relevant to aging such as cardiology, immunology, nutritional medicine, exercise physiology and spirituality. He has technical background in biopharmaceutical and clinical research.
John D. Furber, MS
John Furber is an entrepreneur and scientist who has been studying the biology of aging and regeneration since the 1980s. He was a principal in starting five companies during the 1980s and 90s. Currently he manages Legendary Pharmaceuticals, COMMA which is engaged in the discovery of pharmaceutical drugs and gene therapies to repair and reverse accumulating molecular damage to subcellular mitochondria, lysosomes, nuclei, and extracellular proteins in order to prevent and treat serious, late-onset diseases commonly associated with aging.
He created a wall chart, “The Systems Biology of Human Aging – Network Model”, which is useful, both as a reference, and for introducing new graduate students and scientists to the complexities of human aging physiology. This network format also suggests a means of identifying promising research targets for future therapy development. The currently updated version is maintained on the web at:
Alexander Zhavoronkov, PhD
Dr. Zhavoronkov is working in biotechnology, regenerative medicine and aging economics. He is the director of the Biogerontology Research Foundation, a UK-based think tank for aging research, and is the director of the International Aging Research Portfolio, an open-access repository of biomedical grants. He is the adjunct professor at the Moscow Institute of Physics and Technology and heads the laboratory of regenerative medicine at the Federal Clinical Research Center for Pediatric Hematology, Oncology and Immunology in Moscow.
His company, In Silico Medicine, has the goals of becoming the first and the largest drug discovery company in aging and age-related diseases, and to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment.
And his book, The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy describes how biomedicine will transform our society by allowing people to live longer and to continue working and contributing financially to the economy longer, rather than entering into retirement and draining the economy through pensions and senior healthcare.
Robert J. Morin, M.D.
Chair and Laboratory Director, Department of Pathology, Harbor-UCLA Medical Center
Professor of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA
Bob Morin was the president and chief scientific officer of the American Longevity Association (ALA). ALA sponsored research in aging and the diseases of aging, created communications and held scientific meetings.
João Pedro de Magalhães, PhD
João leads the Integrative Genomics of Aging Group at the Institute of Integrative Biology, University of Liverpool, UK.
After earning his Ph.D. from Escola Superior de Biotecnologia in Porto, Portugal in 1999, João Pedro then did a postdoc from 2004 to 2008 with genomics pioneer George Church at Harvard Medical School in Boston, USA. He developed high-throughput approaches for studying aging, including computational tools and databases, statistical models of mortality, and comparative genomics methods for investigating the evolution of longevity.
Aubrey de Grey, PhD
Dr. de Grey works to identify and promote specific technological approaches to the reversal of the aspects of aging centered around the detailed plan called Strategies for Engineered Negligible Senescence (SENS).
Michael Rose, PhD
Dr. Rose has made significant contributions to the field of aging research. He is a professor in the Department of Ecology and Evolutionary, UC Irvine in Irvine CA USA. His main area of work has been the evolution of aging.
Daniel Wuttke, PhD
Geneticist and bioinformaticist from Germany. He completed his PhD at the University of Liverpool, under the direction of João Pedro de Magalhães. Daniel is active with the international community, making significant contributions to our common purpose. His co-authoring of the paper “Genome-Environment Interactions That Modulate Aging: Powerful Targets for Drug Discovery”, and the title of his thesis “Functional Genomics of Ageing and its Manipulation by Diet” demonstrate his solution-driven approach.
John C. Guerin
John Guerin is a well respected member of the biogerontology community. With a broad base of practical knowledge in aging intervention, he brings project management and accounting experience.